Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: A randomized crossover trial

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 12, 2005, Pages 2649-2655

  Eikelboom, J W ^a   Hankey, G J ^b,c   Thom, J ^b   Claxton, A ^b   Yi, Q ^d   Gilmore, G ^b   Staton, J ^b   Barden, A ^c   Norman, P E ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Aspirin; Clopidogrel; Peripheral arterial disease; Randomized

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; INTERLEUKIN 6; PADGEM PROTEIN; PLACEBO; THROMBOXANE;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; TURBIDIMETRY;

ADENOSINE DIPHOSPHATE; AGED; ARACHIDONIC ACID; ASPIRIN; BIOLOGICAL MARKERS; COLLAGEN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PERIPHERAL VASCULAR DISEASES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 29244439006     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01640.x     Document Type: Article

References (31)

1. Anti-Thrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324: 71-86.
2. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 3): 234S-64S.
3. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-3.
4. Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation 2004; 110: 1706-8.
5. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schror K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
6. Payne DA, Jones CI, Hayes PD, Webster SE, Ross Naylor A, Goodall AH. Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? Thromb Haemost 2004; 92: 89-96.
7. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72.
8. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR. Endogenous biosynthesis of prostacycline and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-88.
9. De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L'Abbate A, Donato L, Patrignani P, Filabozzi P, Patrono C. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur Heart J 1985; 6: 409-17.
10. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003; 41: 966-8.
11. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at risk of high for cardiovascular event. Circulation 2002; 105: 1650-5.
12. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
14. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systemic review of the evidence from randomised trials. Stroke 2000; 31: 1779-84.
15. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
16. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
17. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
18. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
19. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-9.
20. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. Increased sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31: 591-5.
21. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP, Topol EJ, Ellis SG. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001; 88: 672-4.
22. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, Plow E, Topol EJ. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679-84.
23. Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, Moliterno DJ, Ellis SG, Topol EJ. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358-60.
24. Yen MH, Bhatt DL, Chew DP, Harrington RA, Newby LK, Ardissino D, Van der Werf F, White JA, Moliterno DL, Topol EJ. Association between admission white cell count and one-year mortality in patients with acute coronary syndromes. Am J Med 2003; 115: 318-21.
25. Haim M, Boyko V, Goldbourt U, Battler A, Behar S. Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease. The Bezafibrate Infarction Prevention Study. Arch Intern Med 2004; 164: 433-39.
26. Brown DW, Ford ES, Giles WH, Croft JB, Balluz LS, Mokdad AH. Associations between white blood cell count and risk for cerebrovascular disease mortality: NHANES II Mortality Study, 1976-1992. Ann Epidemiol 2004; 14: 425-30.
27. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-8.
28. Leng GC, Fowkes FGR, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313: 1440-4.
29. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 538-45.
30. Robless PA, Okonko Dlintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 2003; 25: 16-22.
31. Bhatt DL, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004; 148: 263-8.